Mr. Qiyu Chen, aged 47, was appointed as a non-executive director of the Company on 15 January 2013 and the chairman of the board of directors on 8 December 2018. Mr. Chen joined Fosun Pharma in April 1994 and has been working there ever since. He has been appointed as a director and the chairman of Fosun Pharma in May 2005 and June 2010, respectively. He is currently an executive director of Fosun International since July 2015, and he has been a co-president from March 2017 to February 2020 and a co-chief executive officer since February 2020. Mr. Chen has been a non-executive director and a vice chairman of Sinopharm Group Co. Ltd. (Stock Exchange stock code: 01099) since May 2010 and September 2014, respectively, a director of Beijing Sanyuan Foods Co., Ltd. (Shanghai Stock Exchange stock code: 600429) since March 2015, and a non-executive director of Babytree Group (Stock Exchange stock code: 01761) since June 2018, respectively. In addition, Mr. Chen holds directorships in various companies invested by Fosun International and its affiliated companies and has served as the co-chairman of New Frontier Health Corporation (listed on the New York Stock Exchange, stock code: NFH) since December 2019. Mr. Chen also served as a director of Maxigen Biotech Inc. (Taiwan Stock Exchange stock code: 01783) from December 2015 to November 2017 and a director of Dian Diagnostics Group Co., Ltd. (Shenzhen Stock Exchange stock code: 300244) from May 2010 to February 2019.

Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, vice president of China Pharmaceutical Innovation and Research Development Association, chairman of Shanghai Biopharmaceutical Industry Association and vice chairman of the Shanghai Society of Genetics.

Mr. Chen obtained a bachelor degree in genetics from Fudan University in the PRC in July 1993 and a master degree of business administration from China Europe International Business School in the PRC in September 2005.

Mr. Wenjie Zhang is Chief Executive Officer and President of Henlius, Executive Director of the Board. 

Mr. Zhang has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, he was the General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. Under his leadership, Amgen built its commercial infrastructure, organization, and competency. He successfully launched Repatha® (evolocumab), Amgen’s first product in China. He joined Amgen in 2014 as Executive Director, Marketing for Japan and Asia Pacific region. Prior to Amgen, Mr. Zhang worked as vice president, Oncology for Roche in Shanghai, China, where he was managing a significant P&L and 850 staff in the oncology franchise marketing business unit. He successfully grew the Roche oncology portfolio including Avastin® (bevacizumab), Tarceva® (erlotinib) and MABTHERA® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing. Before then, Mr. Zhang served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for Asia Pacific region. He successfully launched multiple products in China including Nexavar, Kogenate and Betaferon. Mr. Zhang obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.

Mr. Yifang Wu, aged 50, was appointed as a non-executive director of the Company on 12 June 2015. Mr. Wu is the executive director, president and chief executive officer of Fosun Pharma. Mr. Wu joined Fosun Pharma in April 2004. He was the senior vice president of Fosun Pharma from July 2014 to January 2016 and the senior vice president and chief operating officer of Fosun Pharma from January 2016 to June 2016. He has been the president and chief executive officer of Fosun Pharma since June 2016 and has been appointed as executive director of Fosun Pharma since August 2016. Prior to joining Fosun Pharma Group, Mr. Wu has been a technician, director, production officer, finance director, assistant to director of Xuzhou Biochemical Pharmaceutical Factory, a deputy director of Xuzhou (Wanbang) Biopharmaceuticals Manufactures Plant, the deputy general manager of Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd. and Jiangsu Wanbang Biopharmaceutical Co., Ltd., the president of Jiangsu Wanbang Biopharmaceutical Co., Ltd. (where Xuzhou Biochemical Pharmaceutical Factory, Xuzhou (Wanbang) Biopharmaceuticals Manufactures Plant, Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd. and Jiangsu Wanbang Biopharmaceutical Co., Ltd. were predecessors of Jiangsu Wanbang) and the chairman of Jiangsu Wanbang Biopharmaceutical Co., Ltd. Mr. Wu is also a non-executive director of Sisram Medical Ltd  (Stock Exchange stock code: 01696) since October 2016.

Mr. Wu graduated from Nanjing University of Science and Technology majoring in international commerce in the PRC in 1996 and obtained a master degree in business administration from Saint Joseph’s University in the United States in 2005.

Ms. Guan obtained a bachelor degree of economics from Jiangxi University of Finance and Economics in the PRC in June 2000 and acquired a master degree of professional accountancy from Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as Chinese Certified Public Accountant and a member of The Association of Chartered Certified Accountants.

Dr. Aimin Hui, aged 57, was appointed as a non-executive director of the Company on 10 April 2018. Dr. Hui joined the Fosun Pharma in November 2017 and is currently the senior vice president of Fosun Pharma since November 2017. Prior to joining the Fosun Pharma Group, Dr. Hui was an assistant professor and lecturer at the Faculty of Medicine of University of Tokyo from October 1997 to October 2000, a visiting scientist and researcher at National Cancer Institute in the U.S. from October 2000 to December 2006, a medical director of GE Healthcare Group from January 2007 to December 2008, a medical director of Cephalon, Inc. from January 2009 to April 2010, a clinical oncology director and senior director of Takeda Pharmaceutical Company Limited from April 2010 to November 2015, and a vice president of the global clinical research and development of Sanofi from November 2015 to October 2017.

Dr. Hui obtained a bachelor degree of medicine from Hebei Medical University in the PRC in August 1984 and a doctoral degree from the School of Medicine of Shinshu University in Japan in September 1994.

Mr. Tak Young So, aged 49, was appointed as an independent non-executive director of the Company on 2 September 2019. 

Mr. So has more than 20 years of experience in finance, accounting, investment and private equity businesses with global financial institutions and asset management companies. He started his career as an auditor with Ernst & Young, Hong Kong from February 1993 to December 1994. Mr. So has been the founding and managing partner of FastLane Group since July 2012 and has been a partner of Prospere Capital Limited since January 2018.

Mr. So has previously served various positions, including group audit and project manager of strategic and performance improvement group in the Sydney office of Commonwealth Bank of Australia from January 1995 to January 1998, vice president of global capital market/Asia treasury and vice president of financial controls of Bank of America, Hong Kong from January 1998 to March 2002, head of finance and operations of consumer banking in Hong Kong, head of asset and liability management of Greater China/Asia Pacific and chief financial officer of consumer, commercial and private bank in Hong Kong of ABN AMRO Bank N.V., Hong Kong from March 2002 to January 2005, chief financial officer of Hamon Investment Group, an affiliate of Bank of New York Mellon from February 2005 to August 2007, chief financial officer of Asia Pacific of asset management division for Deutsche Bank, Hong Kong from August 2007 to November 2011, and chief financial officer of PAG Capital from November 2011 to April 2012.

Mr. So received his bachelor of business degree in accounting and finance and his master of business administration degree in banking from the University of Technology in Sydney, Australia in April 1994 and September 1998, respectively. He is a fellow member of the Australian Society of Certified Practising Accounting Australia (FCPA) since August 2011.

Dr. Lik Yuen Chan, aged 51, was appointed as an independent non-executive Director of the Company on 2 September 2019.

Dr. Chan is a world famous academic in liver diseases with extensive achievement and recognition in clinical practice and research teaching. Dr. Chan has served various positions in the Chinese University of Hong Kong, including a director of the centre of liver health since January 2006 and the associate dean of the faculty of medicine since July 2018, and currently the associate dean of external affairs of the faculty of medicine. He is also a professor of the Department of Medicine and Therapeutics.

Dr. Chan received a bachelor’s degree of medicine and surgery from the Chinese University of Hong Kong in December 1992, a doctor’s degree of medicine from the Chinese University of Hong Kong in November 2001 and a master’s degree in business administration from the University of Hong Kong in November 2014. He is a member of Royal College of Physicians of the United Kingdom since November 1995, a fellow of Hong Kong College of Physicians since May 2000, a fellow of Hong Kong Academy of Medicine since June 2000, a fellow of Royal College of Physicians of Edinburgh since July 2003, a fellow of Royal College of Physicians of London since May 2006 and a fellow of American Association for the Study Liver Diseases since October 2016.

Dr. Zhao is a molecular microbiologist. Currently, he has been the chairman of the Advisory Committee of the Key Laboratory of Synthetic Biology at the Institute of Plant Physiology and Ecology (IPPE) of the Chinese Academy of Sciences (CAS), the chair professor of the Department of Microbiology of Health Sciences at The Chinese University of Hong Kong, the professor and director of Department of Microbiology and Microbial Engineering at the School of Life Sciences of Fudan University and the chief scientist of Biomedical Big Data Center at the Shanghai Institute of Nutrition and Health of CAS.

Dr. Ruilin Song, aged 57, was appointed as an independent non-executive Director of the Company on 2 September 2019.

During the time he worked in the Legislative Affairs Office of the State Council of China, Dr. Song was mainly engaged in the legislative review and research of health and medicine for 22 years. He participated in China’s health and drug legislation activities from 1987 to 2006, in charge of the drafting and review of the current Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases, Law of the PRC on Medical Practitioners, Regulations on Medical Institutions, and Regulations for the Supervision and Administration of Medical Devices, etc.

Since 2007, Dr. Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA had finalised dozens of pharmaceutical policy projects in China .

Dr. Song has been working as executive president of PhIRDA (former named China Pharmaceutical Industry Research and Development Association) from November 2009 to September 2019 and as president of PhIRDA since September 2019.

Dr. Song also works as Director of Chinese Pharmaceutical Association (CPA), Standing Director of Chinese Pharmacist Association, Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Expert of Capital Medical Reform Expert Group and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions.

Dr. Song has been an independent director of Jointown Pharmaceutical Group Co., Ltd. (Shanghai Stock Exchange stock code: 600998) from November 2008 to November 2014, an independent director of Zhejiang Jolly Pharmaceutical Co., Ltd.  (Shenzhen Stock Exchange stock code: 300181) from July 2009 to January 2014, an independent director of Shanxi Zhendong Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange stock code: 300158) since June 2015, an independent director of Jiangxi Boya Bio-pharmaceutical Co., Ltd. (Shenzhen Stock Exchange stock code: 300294) since March 2017, an independent director of Tibet Aim Pharm. Inc. (Shenzhen Stock Exchange stock code: 002826) since August 2015, a non-executive director of Luye Pharma Group Ltd. (Stock Exchange stock code: 02186) since March 2017 and an independent director of Chipscreen Biosiences (Shanghai Stock Exchange STAR market stock code: 688321) since June 2018.

Dr. Song obtained a bachelor of laws degree from China University of Political Science and Law in June 1985, a master in business administration degree from China Europe International Business School in November 2004 and a doctor dgree of social and administrative pharmacy from China Pharmaceutical University in December 2018.